Peptide half-life, delivery routes and the bioavailability problem

A peptide's biological activity is only half the research question; the other half is whether it survives long enough, in a usable concentration, at the intended site of action, to produce that activity at all. This pharmacokinetic half of peptide research is frequently underweighted relative to mechanism, but it determines which compounds in this catalogue have progressed toward clinical relevance and which remain preclinical curiosities regardless of how compelling their target biology is.

Unmodified peptides are, as a class, short-lived in circulation. Most are cleared within minutes to a few hours through a combination of renal filtration (peptides below roughly 50 kDa pass the glomerular filter readily), proteolytic degradation by circulating and tissue peptidases, and in some cases receptor-mediated endocytosis and lysosomal breakdown. Sermorelin's minutes-scale half-life, discussed elsewhere in this catalogue's GH-axis coverage, is a direct illustration: it produces a physiological GH pulse precisely because it is cleared quickly, which is a design feature in that specific context rather than a flaw.

Subcutaneous injection remains the default delivery route for the majority of the research peptides covered on this site, including BPC-157, TB-500, Ipamorelin and Sermorelin. The subcutaneous depot allows gradual absorption into systemic circulation via the lymphatic and capillary networks, producing a flatter, more sustained plasma profile than intravenous bolus administration, at the cost of somewhat lower and more variable total bioavailability depending on injection-site blood flow and individual absorption rate.

Intravenous administration bypasses absorption entirely and is standard in the clinical-trial contexts for compounds like SS-31 (elamipretide), where precise, immediate plasma concentration control matters for a mechanism reliant on sustained mitochondrial-membrane exposure. This route is largely impractical outside a clinical or laboratory infusion setting, which is part of why SS-31's translational pathway runs through registered trials rather than the kind of self-administered research protocol common to subcutaneous peptides.

Intranasal delivery is the notable third route in this catalogue, used for Semax and Selank, both derived from the ACTH(4-10) fragment. The nasal mucosa offers direct access to the trigeminal and olfactory pathways with some evidence of limited direct nose-to-brain transport bypassing first-pass hepatic metabolism, which is mechanistically relevant for centrally-acting peptides where systemic exposure is not equivalent to central nervous system exposure. Dolgikh et al. and subsequent Russian-language pharmacokinetic work on Semax describe rapid nasal absorption and short peripheral half-life, consistent with a locally-acting rather than systemically-persistent profile.

Chemical modification strategies exist specifically to address the short-half-life problem where a sustained plasma profile is mechanistically desirable. The Drug Affinity Complex (DAC) technology used in CJC-1295 covalently links the peptide to a maleimide group that binds circulating albumin, extending half-life from minutes (unmodified GHRH analogues) to several days by piggybacking on albumin's own slow clearance. This is a fundamentally different strategy from FOX04-DRI's D-retro-inverso backbone reversal discussed elsewhere in this catalogue, which achieves stability through protease resistance rather than carrier binding.

Cyclisation is a third stability strategy, used in Ipamorelin's design lineage among others, where constraining the peptide backbone into a ring structure reduces the conformational flexibility that many proteases require to access a cleavage site. This tends to improve stability without the added molecular weight of an albumin-binding modification, though the trade-off is a more constrained structure-activity relationship during initial peptide design.

Oral bioavailability remains essentially unsolved for this entire compound class. Peptides face a hostile gastrointestinal environment (low gastric pH, extensive protease activity, poor intestinal-epithelium permeability for molecules of this size and polarity), and none of the peptides covered on this site is designed or evidenced for oral administration. Where oral peptide products exist in the broader supplement market, bioavailability data is generally absent or unfavourable, and this catalogue does not treat oral delivery as an established route for any listed compound.

The research implication is that delivery-route selection is not a logistical afterthought but a design decision inseparable from a peptide's intended mechanism: a compound requiring sustained systemic exposure needs either a naturally long half-life, an albumin-binding modification, or an infusion protocol, while a compound intended for local or CNS-proximate action may be better served by a short-half-life, route-restricted approach. Evaluating any new peptide candidate for this catalogue should include this pharmacokinetic question as a first-order item alongside mechanism, not as a secondary formulation detail.